RxDoctor Payments DataLook up a doctor →

Mario Chan, MD

Endocrinology, Diabetes & Metabolism · Arlington Heights, ILNPI 1104975176

Payments from drug & device makers

$32,314in general payments, 2019–2025

Across 1,328 payments — averaging $24.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$4K
  • Dexcom, Inc.$3K
  • Boehringer Ingelheim$3K
  • Amgen$2K
  • Novo Nordisk$2K
  • Corcept Therapeutics$2K
  • plus $17K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC188$3,876
Dexcom, Inc.89$3,319
Boehringer Ingelheim83$2,615
Amgen(2 entities)72$2,019
Novo Nordisk96$1,812
Corcept Therapeutics48$1,648
AstraZeneca(2 entities)59$1,389
Sanofi-aventis U.S. LLC57$1,310
Abbott96$1,303
Mannkind Corporation50$1,026
Amneal Pharmaceuticals LLC47$875
Bayer25$762
Esperion Therapeutics, Inc.28$732
Xeris Pharmaceuticals, Inc.26$620
Tandem Diabetes Care, Inc.35$609
OPKO Pharmaceuticals, LLC8$606
Radius Health, Inc.19$570
Amarin Pharma, Inc.13$524
Neurocrine Biosciences, Inc.12$496
Medtronic(2 entities)14$477
Ascendis Pharma Endocrinology Inc17$473
Recordati_rare_diseases_inc.14$429
Ascensia Diabetes Care US Inc.15$423
Merck27$419
Antares Pharma, Inc.29$412
AbbVie22$380
IBSA Pharma Inc.18$291
Madrigal Pharmaceuticals8$283
Insulet Corporation5$230
Astellas Pharma US Inc8$215
Johnson & Johnson9$204
BETA Bionics, Inc.9$198
Novartis7$183
Cequr Corporation2$163
Shire North American Group Inc7$142
Kyowa Kirin, Inc.5$124
Ultragenyx Pharmaceutical Inc.6$103
Lifescan, Inc.5$98
Amryt Pharma Holdings Ltd4$81
Amphastar Pharmaceuticals, Inc.4$80
Vivus LLC5$76
Nevro Corp.3$63
Rhythm Pharmaceuticals, Inc.2$55
Embecta Corp.2$50
Halozyme Inc2$42
Ipsen Biopharmaceuticals, Inc3$41
Companion Medical, Inc.2$39
Echosens North America, Inc.3$38
Zealand Pharma US, Inc.2$37
Valeritas, Inc.2$37
Clarus Therapeutics Inc.2$36
Acella Pharmaceuticals, LLC2$34
BD1$32
Verity Pharmaceuticals Inc.1$32
Organogenesis Inc.1$29
Jazz Pharmaceuticals Inc.1$28
Chiesi USA, Inc.1$22
Eisai Inc.1$21
Roche Diabetes Care, Inc.1$18
Azurity Pharmaceuticals, Inc.1$17

How this compares

$32,314 in reported general payments places this provider in the 85th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.

See all endocrinology, diabetes & metabolism providers in Illinois →

Medicare billing

Part B allowed, 2024
$191,102
Medicare patients
490
Services billed
1,969

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Arlington Heights

See the full list for Illinois →

Where these figures come from

Is this you, or does something look wrong? →